PDF(Pubmed)
Abstract：
BACKGROUND: PET imaging of the translocator protein (TSPO) is used to assess in vivo brain inflammation. One of the main methodological issues with this method is the allelic dependence of the radiotracer affinity. In Alzheimer\'s disease (AD), previous studies have shown similar clinical and patho-biological profiles between TSPO genetic subgroups. However, there is no evidence regarding the effect of the TSPO genotype on cerebrospinal-fluid biomarkers of glial activation, and synaptic and axonal damage.
METHODS: We performed a trans-sectional study in early AD to compare cerebrospinal-fluid levels of GFAP, YKL-40, sTREM2, IL-6, IL-10, NfL and neurogranin between TSPO genetic subgroups.
RESULTS: We recruited 33 patients with early AD including 16 (48%) high affinity binders, 13 (39%) mixed affinity binders, and 4/33 (12%) low affinity binders. No difference was observed in terms of demographics, and cerebrospinal fluid levels of each biomarker for the different subgroups.
CONCLUSIONS: TSPO genotype is not associated with a change in glial activation, synaptic and axonal damage in early AD. Further studies with larger numbers of participants will be needed to confirm that the inclusion of specific TSPO genetic subgroups does not introduce selection bias in studies and trials of AD that combine TSPO imaging with cerebrospinal fluid biomarkers.
METHODS: We performed a trans-sectional study in early AD to compare cerebrospinal-fluid levels of GFAP, YKL-40, sTREM2, IL-6, IL-10, NfL and neurogranin between TSPO genetic subgroups.
RESULTS: We recruited 33 patients with early AD including 16 (48%) high affinity binders, 13 (39%) mixed affinity binders, and 4/33 (12%) low affinity binders. No difference was observed in terms of demographics, and cerebrospinal fluid levels of each biomarker for the different subgroups.
CONCLUSIONS: TSPO genotype is not associated with a change in glial activation, synaptic and axonal damage in early AD. Further studies with larger numbers of participants will be needed to confirm that the inclusion of specific TSPO genetic subgroups does not introduce selection bias in studies and trials of AD that combine TSPO imaging with cerebrospinal fluid biomarkers.
摘要：
背景：易位蛋白（TSPO）的PET成像用于评估体内脑部炎症。该方法的主要方法学问题之一是放射性示踪剂亲和力的等位基因依赖性。在阿尔茨海默病（AD）中，先前的研究表明，TSPO遗传亚组之间的临床和病理生物学特征相似。然而,没有证据表明TSPO基因型对神经胶质激活的脑脊液生物标志物的影响，突触和轴突损伤。
方法：我们在早期AD中进行了一项横断面研究，以比较脑脊液中GFAP的水平，YKL-40，sTREM2，IL-6，IL-10，NfL和神经颗粒蛋白之间的TSPO遗传亚群。
结果：我们招募了33例早期AD患者，包括16例（48%）高亲和力结合者，13（39%）混合亲和粘合剂，和4/33(12%)低亲和力结合剂。在人口统计学方面没有观察到差异，以及不同亚组的每种生物标志物的脑脊液水平。
结论：TSPO基因型与神经胶质激活的变化无关，早期AD的突触和轴突损伤。需要对更多参与者进行进一步研究，以确认特定TSPO遗传亚群的纳入不会在将TSPO成像与脑脊液生物标志物相结合的AD研究和试验中引入选择偏倚。
方法：我们在早期AD中进行了一项横断面研究，以比较脑脊液中GFAP的水平，YKL-40，sTREM2，IL-6，IL-10，NfL和神经颗粒蛋白之间的TSPO遗传亚群。
结果：我们招募了33例早期AD患者，包括16例（48%）高亲和力结合者，13（39%）混合亲和粘合剂，和4/33(12%)低亲和力结合剂。在人口统计学方面没有观察到差异，以及不同亚组的每种生物标志物的脑脊液水平。
结论：TSPO基因型与神经胶质激活的变化无关，早期AD的突触和轴突损伤。需要对更多参与者进行进一步研究，以确认特定TSPO遗传亚群的纳入不会在将TSPO成像与脑脊液生物标志物相结合的AD研究和试验中引入选择偏倚。
